Strong cytochrome P450 (CYP) 3A4 inhibitors may induce Cushing syndrome and subsequent adrenal insufficiency when administered concurrently with corticosteroids. This drug–drug interaction has been well described with HIV protease inhibitors. A similar drug–drug interaction with corticosteroids and other strong CYP 3A4 inhibitors (antifungals [imidazoles]) has recently been reported but remains less well known. To our knowledge, we report the first case of probable drug-induced Cushing syndrome with subsequent adrenal insufficiency as a result of concomitant oral voriconazole with intranasal mometasone and inhaled fluticasone administration as well as a review of the current literature supporting this drug–drug interaction.
FoisyMMYakiwchukEMChiuI. Adrenal suppression and Cushing’s syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med. 2008;9(6):389–396.
2.
Flonase [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2015.
3.
SaberiPPhengrasamyTNguyenDP. Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management. HIV Med. 2013;14(9):519–529.
4.
BoydSDHadiganCMcmanusM. Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone. J Acquir Immune Defic Syndr. 2013;63(3):355–361.
5.
HallJJHughesCAFoisyMM. Iatrogenic cushing syndrome after intra-articular triamcinolone in a patient receiving ritonavir-boosted darunavir. Int J STD AIDS. 2013;24(9):748–752.
6.
PilmisBCoignard-BiehlerHJullienV. Cushing’s syndrome induced by posaconazole. Antimicrob Agents Chemother. 2013;57(11):5727–5728.
7.
BlondinMCBeauregardHSerriO. Iatrogenic Cushing syndrome in patients receiving inhaled budesonide and itraconazole or ritonavir: two cases and literature review. Endocr Pract. 2013;19(6):e138–e141.
8.
GilchristFJCoxKJRoweR. Itraconazole and inhaled fluticasone causing hypothalamic-pituitary-adrenal axis suppression in adults with cystic fibrosis. J Cyst Fibros. 2013;12(4):399–402.
9.
NaefRSchmidCHoferM. Itraconazole comedication increases systemic levels of inhaled fluticasone in lung transplant recipients. Respiration. 2007;74(4):418–422.
10.
BollandMJBaggWThomasMG. Cushing’s syndrome due to interaction between inhaled corticosteroids and itraconazole. Ann Pharmacother. 2004;38(1):46–49.
11.
ParmarJSHowellTKellyJ. Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis. Thorax. 2002;57(8):749–750.
12.
De WachterEMalfrootADe SchutterI. Inhaled budesonide induced Cushing’s syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450. J Cyst Fibros. 2003;2(2):72–75.
13.
SkovMMainKMSillesenIB. Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide. Eur Respir J. 2002;20(1):127–133.
14.
De WachterEVanbessienJDe SchutterI. Rapidly developing Cushing syndrome in a 4-year-old patient during combined treatment with itraconazole and inhaled budesonide. Eur J Pediatr. 2003;162(7-8):488–489.
15.
RaaskaKNiemiMNeuvonenM. Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole. Clin Pharmacol Ther. 2002;72(4):362–369.
16.
St ClairKMaguireJD. Role of fluconazole in a case of rapid onset ritonavir and inhaled fluticasone-associated secondary adrenal insufficiency. Int J STD AIDS. 2012;23(5):371–372.
17.
HooverWCBrittonLJGardnerJ. Rapid onset of iatrogenic adrenal insufficiency in a patient with cystic fibrosis-related liver disease treated with inhaled corticosteroids and a moderate CYP3A4 inhibitor. Ann Pharmacother. 2011;45(7-8):e38.
18.
SchmidG.Addition of inhaled fluticasone to systemic immunosuppression after lung transplantation: Cushing’s syndrome in patients on itraconazole comedication. Transplantation. 2003;76(1):263–264.
19.
Vfend [package insert]. New York, NY: Pfizer Inc; 2014.
20.
JonesWChastainCAWrightPW. Iatrogenic Cushing syndrome secondary to a probable interaction between voriconazole and budesonide. Pharmacotherapy. 2014;34(7):e116–e119.
21.
NiemanLK. Cushing’s syndrome: update on signs, symptoms and biochemical screening. Eur J Endocrinol. 2015;173(4):m33–m38.
HornHRHanstenPDChanLN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41(4):674–680.
24.
DeutschbeinTUngerNMannS. Diagnosis of secondary adrenal insufficiency: unstimulated early morning cortisol in saliva and serum in comparison with the insulin tolerance test. Horm Metab Res. 2009;41(11):834–839.
25.
DoltonMJRayJEChenSC. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother. 2012;56(9):4793–4799.
26.
HamadaYSetoYYagoK. Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical metaanalysis. J Infect Chemother. 2012;18(4):501–507.
27.
MitsaniDNguyenMHShieldsRK. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother. 2012;56(5):2371–2377.
28.
DaveluyARaignouxCMiremont-SalaméG. Drug interactions between inhaled corticosteroids and enzymatic inhibitors. Eur J Clin Pharmacol. 2009;65(7):743–745.
29.
MalimardMGirodetPOPolletC. Inhaled corticosteroids and adrenal insufficiency. Drug Saf. 2008;31(9):769–774.
RiedlMMaierCZettinigG. Long term control of hypercortisolism with fluconazole: case report and in vitro studies. Eur J Endocrinol. 2006;154(4):519–524.
34.
VarisTKivistoKTBackmanJT. Itraconazole decreases the clearance and enhances the effect of intravenously administered methylprednisolone in healthy volunteers. Pharmacol Toxicol. 1999;85(1):29–32.
